The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030{RootsAnalysis}
Roots Analysis hasdone a detailed study on Digital Health Market:Focus on Digital Therapeutics (2nd Edition),2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution andCombination Solution), Type of Therapy (Curative and Preventive), and Purposeof Solution (Medication Replacement and Medication Augmentation” covering key aspects of theindustry’s evolution and identifying potential future growth opportunities.
To order this 500+ page report, which features160+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html
Key Market Insights
§ Eminent representatives from companies acrossthe world attest to the fact that there is growing interest in the digitaltherapeutics market, highlighting the prevalent and anticipated trends inR&D and adoption
§ Over 100 industry players are engaged inevaluating the potential of several prescription (validated through clinicalresearch) digital therapeutic solutions to prevent / treat various chronicdiseases
§ The pipeline features a variety of digitalhealth applications and therapy solutions that are in different stages ofdevelopment, being investigated for diverse purposes, across a wide-range ofclinical conditions
§ These solutions have demonstratedapplicability across more than 20 therapeutic areas; several products have beenmarketed / approved for the treatment or prevention of mental health problemsand metabolic disorders
§ In pursuit of a competitive edge, digitaltherapeutic solution developers are focusing on the integration of advancedfeatures into their respective products and affiliated offerings
§ In the last few years, over 220 clinicaltrials evaluating the potential benefits of digital therapeutics in close to80,000 patients, have been registered; most of these were / are being conductedat various centers in the US
§ Apart from theclinical benefit, cost is another key determinant of the acceptance andadoption of such novel interventions; pricing strategy matrix is likely toassist players to evaluate competitive market prices for solutions
§ To support the ongoinginnovation in this field, several private and public investors have madesubstantial capital investments, amounting to approximately USD 1.7 billion, invarious initiatives of stakeholders
§ The growing interestin this field is reflected by the increase in partnership activity, involvingboth international and indigenous stakeholders, across different geographicalmarketplaces
§ In order to promote the adoption ofproprietary digital health solutions, developers are actively exploring variousmarketing strategies in order to highlight key features of their productsacross a number of platforms
§ Several digital monitoring / diagnosticsolutions are also available to manage / diagnose patients for various chronicdiseases; specifically, these remote monitoring solutions have gained interestduring COVID-19
§ Given the rising incidence of chronic clinicalconditions and a growing pipeline of modern medicines to treat such diseases,the market for evidence-based digital therapeutics is poised to grow at a CAGRof ~20% till 2030
§ The projected marketopportunity is anticipated to be well-distributed across different therapeuticareas, distribution channels and key geographical regions
For more information, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
Tableof Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with DigitalHealth Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for DiseaseControl and Prevention (CDC)
3.5.1.4. Health Insurance Portability and AccountabilityAct (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration(USFDA) Regulations for Digital Therapeutics
3.5.2. Product Development and CommercializationPath for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall MarketLandscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: AdditionalInformation
4.3.1. Analysis by Prescription Requirement
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number ofDigital Therapeutics Solutions
4.6. LeadingDevelopers: 4D Bubble Analysis based on Portfolio Strength, Target Indicationand Company Size
4.7. Grid Representation: Analysis by Statusof Development, Type of Solution and Therapeutic Area
4.8. Tree Map Representation: Analysis byTherapeutic Area and Company Size
4.9. World Map Representation: Analysis ofRegional Activity
4.10. Digital Therapeutics: Information onAdditional Companies
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Key Therapeutic Areas
5.4.1. Cardiovascular Disorders
5.4.1.1. Product Competitiveness Analysis
5.4.2. Mental Health Problems
5.4.2.1. Product Competitiveness Analysis
5.4.3. Metabolic Disorders
5.4.3.1. Product Competitiveness Analysis
5.4.4. Neurological Disorders
5.4.4.1. Product Competitiveness Analysis
5.4.5. Substance Use Disorders
5.4.5.1. Product Competitiveness Analysis
5.4.6. Other Therapeutic Areas
5.4.6.1. Product Competitiveness Analysis
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Mindmaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical TrialAnalysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled andTrial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Players: Analysis by Numberof Registered Trials
7.3.8 Leading Digital Therapeutic Solutions:Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Geographical Analysis by Number of ClinicalTrials
7.3.12. Geographical Analysis by Trial RecruitmentStatus
7.3.13. Geographical Analysis by Enrolled PatientPopulation
7.4. Clinical End-Points Analysis
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Digital Therapeutics: Funding andInvestment Analysis
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Therapy
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Geography
8.3.7. Most Active Players: Analysis by Number ofFunding Instances
8.3.8. Most Active Players: Analysis by Amount ofFunding
8.3.9. Most Active Investors: Analysis by Number ofInstances
8.4 Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: Recent Partnershipsand Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Type of Partnership and Year ofPartnership
9.3.2.2. Analysis by Type of Partnership and CompanySize
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Type of Partner and Year ofPartnership
9.3.3.2. Analysis by Type of Partner and Type ofPartnership
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Therapy and Type ofPartnership
9.3.4.2. Analysis by Type of Therapy and Type of Partner
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Therapeutic Area and Year ofPartnership
9.3.5.2 Analysis by Therapeutic Area and Type ofPartner
9.3.6. Most Active Players: Analysis by Number ofPartnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and IntracontinentalAgreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by DigitalTherapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activitiesthrough Official Websites
10.2.5. Adoption of Different Business Models andPricing Strategies
10.2.5.1.B2C Business Model
10.2.5.2.B2B Business Model
10.2.5.2.B2B2C Business Model
10.2.6. Undertaking Various Promotional Activitiesthrough Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3 Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price EvaluationHypothesis
11.3.3. Results and Interpretation
11.3.3.1.Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2.Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3.Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4.Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5.Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6.Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7.Product Price Evaluation Matrix: Based on Course Duration
11.3.3.8.Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market,2020-2030
12.4. Global Digital Therapeutics Market:Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for StandaloneSoftware Applications, 2020-2030
12.4.2. DigitalTherapeutics Market for Combination Offerings (Software Application + Device +Personal Coach), 2020-2030
12.4.3. DigitalTherapeutics Market for Combination Offerings (Software Application + Device +AI Support), 2020-2030
12.4.4. DigitalTherapeutics Market for Combination Offerings (Software Application + Device),2020-2030
12.4.5. DigitalTherapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030
12.4.6. DigitalTherapeutics Market for Combination Offerings (Software Application + PersonalCoach), 2020-2030
12.4.7. Digital Therapeutics Market for Other Types ofSolutions, 2020-2030
12.5. Global Digital Therapeutics Market:Distribution by Purpose of Solution
12.5.1. Digital Therapeutics Market for MedicationReplacement Solutions, 2020-2030
12.5.2. Digital Therapeutics Market for MedicationAugmentation Solutions, 2020-2030
12.6. Global Digital Therapeutics Market:Distribution by Type of Therapy
12.6.1 Digital Therapeutics Market for CurativeTherapy, 2020-2030
12.6.2. Digital Therapeutics Market for PreventiveTherapy, 2020-2030
12.7. Global Digital Therapeutics Market:Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model(Patients and Caregivers), 2020-2030
12.7.2. Digital Therapeutics Market for B2B Model(Healthcare Providers, Payers, Employersand Pharmaceutical Companies), 2020-2030
12.8. Global Digital Therapeutics Market:Distribution by Therapeutic Area
12.8.1. Digital Therapeutics Market for CardiovascularDisorders, 2020-2030
12.8.2. Digital Therapeutics Market for Chronic Pain,2020-2030
12.8.3. Digital Therapeutics Market for Mental HealthProblems, 2020-2030
12.8.4. Digital Therapeutics Market for MetabolicDisorders, 2020-2030
12.8.5. Digital Therapeutics Market for NeurologicalDisorders, 2020-2030
12.8.6. Digital Therapeutics Market for RespiratoryDisorders, 2020-2030
12.8.7. Digital Therapeutics Market for SleepDisorders, 2020-2030
12.8.8. Digital Therapeutics Market for Substance UseDisorders, 2020-2030
12.8.9. Digital Therapeutics Market for Other Disorders,2020-2030
12.9. Global Digital Therapeutics Market:Distribution by Geography
12.9.1 Digital Therapeutics Market in North America,2020-2030
12.9.1.1Digital Therapeutics Market in the US, 2020-2030
12.9.1.2Digital Therapeutics Market in Canada, 2020-2030
12.9.2 Digital Therapeutics Market in Europe,2020-2030
12.9.2.1.Digital Therapeutics Market in France, 2020-2030
12.9.2.2.Digital Therapeutics Market in Germany, 2020-2030
12.9.2.3.Digital Therapeutics Market in Italy, 2020-2030
12.9.2.4.Digital Therapeutics Market in Spain, 2020-2030
12.9.2.5.Digital Therapeutics Market in the UK, 2020-2030
12.9.2.6.Digital Therapeutics Market in Rest of Europe, 2020-2030
12.9.3. Digital Therapeutics Market in Asia-Pacific,2020-2030
12.9.3.1.Digital Therapeutics Market in Australia, 2020-2030
12.9.3.2.Digital Therapeutics Market in China, 2020-2030
12.9.3.3.Digital Therapeutics Market in India, 2020-2030
12.9.3.4.Digital Therapeutics Market in Japan, 2020-2030
12.9.3.5.Digital Therapeutics Market in South Korea, 2020-2030
12.9.3.6.Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030
12.9.4. Digital Therapeutics Market in Rest of theWorld, 2020-2030
13. CASE STUDY: IMPACT OF CORONAVIRUSOUTBREAK
13.1. Chapter Overview
13.2. Impact of Coronavirus Pandemic on DigitalTherapeutics
13.2.1. Impact on Future Market Opportunity forDigital Therapeutic Solutions Market
13.3. Recuperative Strategies for DeveloperBusinesses
13.3.1. Strategies for Implementation in the Short /Mid Term
13.3.2. Strategies for Implementation in the Long Term
14. REMOTE DIGITAL MONITORING / DIAGNOSTICSOLUTIONS
14.1. Chapter Overview
14.2. An Introduction to Remote DigitalMonitoring / Diagnostic Solutions
14.3. Remote Digital Monitoring / DiagnosticSolutions: Overall Market Landscape
14.3.1. Analysis by Status of Development
14.3.2. Analysis by Type of Solution
14.3.3. Analysis by Target Disease Indication(s)
14.3.4. Analysis by Therapeutic Area
14.3.5. Grid Representation: Analysis by Status ofDevelopment, Type of Solution, and TherapeuticArea
14.4. Remote Digital Monitoring / DiagnosticSolutions: List of Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters
14.5. Remote Digital Monitoring / DiagnosticSolutions: Company Profiles
14.5.1. AliveCor
14.5.1.1.Company Snapshot
14.5.1.2.Product Portfolio
14.5.1.3.Recent Developments and Future Outlook
14.5.2. Bioserenity
14.5.2.1.Company Snapshot
14.5.2.2.Product Portfolio
14.5.2.3.Recent Developments and Future Outlook
14.5.3. Cue
14.5.3.1.Company Snapshot
14.5.2.2.Product Portfolio
14.5.2.3.Recent Developments and Future Outlook
14.5.4. Kinsa
14.5.4.1.Company Snapshot
14.5.4.2.Product Portfolio
14.5.4.3.Recent Developments and Future Outlook
14.6. Remote Digital Monitoring / DiagnosticSolutions: Funding and Investment Analysis
14.6.1. Types of Funding
14.6.2. Remote Digital Monitoring / DiagnosticSolutions: List of Funding and Investments
14.6.2.1.Analysis by Number of Funding Instances
14.6.2.2.Analysis by Amount Invested
14.6.2.3.Analysis by Type of Funding
14.6.2.4.Most Active Players: Analysis by Number of Funding Instances
14.6.2.5.Most Active Players: Analysis by Amount Invested
14.6.2.6.Most Active Investors: Analysis by Number of Funding Instances
14.7. Concluding Remarks
15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors
15.2.1. Strengths
15.2.2. Weaknesses
15.2.3. Opportunities
15.2.4. Threats
16. DIGITAL SOLUTIONS: RECENT TRENDS ANDFUTURE OPPORTUNITIES
16.1. Chapter Overview
16.2. Prevalent Trends Related to DigitalTherapeutics
16.2.1. Emerging Focus Areas
16.2.2. Key Historical Trends
16.2.3. Geographical Distribution of Activity
16.3. Trends Shaping the Future of DigitalTherapeutics
16.3.1. Digital Solutions Closing the Digital Gap
16.3.2. Increasing Focus on Patient Centric Models
16.3.3. Applicability across a Variety of DiseaseIndications
16.3.4. Increasing Emphasis on Real-World Evidence inResearch and Development
16.3.5. Advances in IT and Computing Power to FosterFuture Innovation
16.4. Improving the Future Health: OpportunitiesBeyond Digital Therapeutics
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Vida Health
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Stephanie Tilenius,Co-Founder and Chief Executive Officer
17.3. Canary Health
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Adam Kaufman, Chief Executive Officer
17.4. Floreo
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Vijay Ravidran, Chief Executive Officer
17.5. Somatix
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Eran Ofir, Chief Executive Officer
17.6. Tilak Healthcare
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Edouard Gasser, Chief Executive Officer
17.7. Wellthy Therapeutics
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Palakh R Saraogi, VicePresident Marketing, Arani Sarkra, SeniorManager Consumer Marketing, and Yolande D’Mello, Marketing and PublicRelations
17.8. Voluntis
17.8.1. Company Snapshot
17.8.2. Interview Transcript: Amelie Janson,Communications Manager
17.9. Anonymous
17.9.1. Interview Transcript: Anonymous, Founder andChief Executive Officer
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
